Pharma Mergers: FTC Should Consider Monitoring R&D, Assessing PBM Contracts, Experts Advise

Panelists at FTC/DOJ workshop suggest new remedies to ensure pharma mergers are not anti-competitive. The commission should support scientists and ensure R&D continues, one expert says.